The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer

Jean L. Grem, Seth M. Steinberg, Alice P. Chen, Manette McAtee, Ellen Cullen, J. Michael Hamilton, Carmen J. Allegra

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

To determine if pre-treatment serum carcino-embryonic antigen (CEA) levels or changes in CEA values during treatment have prognostic value, we reviewed five prior fluorouracil/leucovorin-based trials and identified 125 colorectal cancer patients with no prior chemotherapy for metastatic disease in whom CEA values were available. Although pre-treatment serum CEA values did not predict for clinical response or time to progression, serial monitoring of CEA appeared to be useful in patients with an elevated pretreatment CEA, particularly when a decrease in CEA occurred in concert with radiographic evidence of disease response. The CEA nadir was a strong prognostic variable with respect to time to disease progression. A consistent rise in CEA values over the minimum value signals the need for radiographic reassessment of the patient's disease status to rule out disease progression.

Original languageEnglish (US)
Pages (from-to)559-567
Number of pages9
JournalOncology reports
Volume5
Issue number3
DOIs
StatePublished - 1998

Keywords

  • Carcinoembryonic antigen
  • Colon cancer
  • Prognostic indicators
  • Rectal cancer
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Grem, J. L., Steinberg, S. M., Chen, A. P., McAtee, M., Cullen, E., Michael Hamilton, J., & Allegra, C. J. (1998). The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. Oncology reports, 5(3), 559-567. https://doi.org/10.3892/or.5.3.559